Kheirabadi GR, et al. - Researchers investigated the efficacy of pregabalin in reducing opioid withdrawal symptoms. In this double-blind clinical-trial, noninjecting opioid users diagnosed with opioid dependence and referred to the Addiction Treatment Center of Khorshid Hospital in Isfahan, Iran, in 2015 and 2016, were included and were divided into intervention and control groups. Both groups received Buprenorphine for the routine management of opioid withdrawal syndrome. Additionally, the intervention group initiated 450 mg/d of pregabalin while the control group initiated placebos. As per outcomes, the 450-mg/day pregabalin regimen did not seem superior to the placebo for controlling the symptoms of opioid withdrawal syndrome.